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ABSTRACT 
Cervical cancer is the fourth most common cancer in women 
worldwide and it is the most common cancer in women aged 
15 to 44 years. The national cervical screening programme 
was introduced in Malta in 2016, aiming to increase the 
detection rate of pre-malignant, low- and high-grade cervical 
disease. The Human Papillonna Virus (HPV) is the main cause 
of cervical cancer and with the HPV vaccine as part of the 
national immunization programme, we have a strong and 
useful weapon in the prevention of infection with this virus. 
CERVICAL CANCER 
Cervical cancer originates at the transformation zone 
which surrounds the opening of the cervix leading into the 
endocervical canal (Figure 1 ). The ectocervix is a layer of 
squamous. cells on the outer surface of the cervix whilst the 
endocervix consists of mucus producing glandula r columnar 
cells making up the inner surface of the cervix. If cells from 
the ectocervix become cancerous it will lead to a squamous 
cell carcinoma, which is the most common type of cervical 
cancer. The g landular cell s of the endocervix can also become 
cancerous, leading to an adenocarcinoma of the cervix. 1 
Less commonly, cervical cancers have features of both 
squamous. cell carcinomas and adenocarcinomas. These are 
called adenosquamous carcinomas or mixed carcinomas. 
Cervical cancer can be detected at a pre-malignant 
stage due to presence of dyskaryotic atypical cells within the 
squamous. epithelium, better known as cervica I intra-epithelial 
neoplasia (CIN) or cervical dysplasia. CIN is a histological 
diagnosis and depends on the extent of invasion.CINI refers 
to mild dysplasia whereby atypical cells are found only in 
the lower 1/3 of the epithelium. CIN II refers to moderate 
dysplasia with atypical cells found in the lower 2/3 of 
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Figure 1: Female Reproductive System2 
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epitheli um. CIN Ill refers to carcinoma in situ, where atypical 
cells occupy the full thickness of the epithelium. In CIN Ill the 
cells are similar to malignant lesions but show no invasion 
beyond the epithelial basement membrane.3 
Cervical cancer is the commoniest type of cancer in 
women under the age of 35 years in developed countries. 
It is the fourth most common cane-er in women worldwide 
and the second most common in low- and middle-income 
countries.• It has an overall 65% five-year survival and is 
thus a major cause of morbidity and mortality from cancer.3 
Cervical cancer isn't always obviou·s and may not cause any 
symptoms until it's reached an advanced stage. In most cases, 
vaginal bleeding is the first noticeable symptom. The most 
common symptoms of cervical cancer include intermenstrual, 
postcoital or postmenopausal bleeding. Cervical cancer 
may also be associated with vaginal discharge, dyspareunia 
or pelvic pain.5 
RISK FACTORS 
The major cause of cervical cancers is Human Papilloma 
Virus (HPV). There are over 130 strains of HPV with the 
majority being harmless, causing genital warts, and some 
others being associated with cervical cancer.3 HPV types 
16 and 18 are responsible for around 70% cervical cancer 
cases.• HPV18 is mainly a risk factor for the development of 
adenocarcinoma whereas HPV16 is associated with both 
squamous cell and adenocarcinoma. Other high-risk strains 
include HPV type 13, 31, 33.3 For most people, the immune 
system clears the HPV infection spontaneously within 2 
years. In cases of persistent infection, especially with a high· 
risk type of HPV there is a higher risk of developing1 CIN 
leading to cervical cancer.6 The risk is even higher in women 
who have other sexually transmitted infections alongside of 
HPV; especially Herpes Simplex Type 2 virus. 
Other risk factors include: 
• Immunodeficiency 
• Smoking 
• Taking the oral contraceptive pill for more than five years 
• High parity6 
• Becoming sexually active at a younger age (especially < 18 
years).7 
PREVENTION AND EARLY DETECTION 
Regular cervical screening can detect CIN changes and is 
a simple and effective way to pick up cervical cell changes. 
The cervical screening test was independently invented in 
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the 1920s by Drs Georgios Papanikolaou and Aurel Babe~ 
and narried after Papanikolaou. The German virologist, 
Prof. Harald zur Hausen discovered the link between HPV 
and cervical cancer and was awarded the Nobel Prize for 
Physiology and Medicine in 2008 for this d iscovery. 
Conventional Papanicolaou (PAP) smears can give false 
results due to inadequate sampling and slide preparation, 
and errors in laboratory detection and interpre tation. On 
the other hand liquid-based cervical cytology has been 
developed to improve the d iagnostic reliability of the test. 
Cervical cells are rinsed in a .liquid based medium, which 
prevents false results due to blood or other potentially 
obscuring materials. Liquid-based cytology als.o allows 
for additional testing for HPV from the same sample in 
high risk cases.8 
An abnormal cervical screening test result does not mean 
cancer. Most abnormal results are due to signs. of HPV, the 
presence of treatable precancerous cells (CIN). or both, rather 
than cancer itself. 6 
With an abnormal smear resu lt, the next investigation in 
line would be colposcopy +/- biopsy. This procedure also 
allows for staining with acetic acid and Lugol's iodine which 
help d etect abnormal cells, as well as biopsies of the cervix. 
CINI commonly regresses spontaneously but if left untreated 
CIN II and Ill will usually develop into cervical cancer over a 
period of 10 years, therefore detection and treatment are 
crucia l. CIN can be treated by doing a large loop excision 
of the transformation zone using cutting diathermy under 
local anaesthetic. Established cervical cancer requires further 
investigation to determine FIGO classification and histology 
for staging. Treatment ranges from cone biopsy to radical 
hysterectomy+/- radiotherapy and chemotherapy.3 
Practising safer sex by us ing barrier methods like 
condoms will reduce the risk of getting HPV and passing it on 
but is not 100% effective. There are now vaccines available 
to prevent HPV infection. HPV vaccination provides safe, 
effective, and lasting protection against the HPV infections 
that most commonly cause cancer. These vaccines do not 
protect against all kinds of H PV, therefore one still needs 
to take part in cervical screening, even if vaccinated.6 
The vaccines available are Gardasil 9 (recombinant HPV 
nonavalent vaccine, Types 6,. 11 , 16, 18, 31 , 33, 45, 52, and 
58) and Cervarix (recombinant HPV bivalent vaccine, Types 
16 and 18). Both vaccines are recommended from the 
age of 9 years.9 
Between the ages of 9 and 14, the vaccine is g iven in 2 
doses spaced 6 months apart. After the age of 14, the course 
is of 3 doses, with the first 2 doses given 1 month apart and 
the third dose given 5 months after the second dose. In 
Malta, HPV vaccination is part of the National Immunisation 
Schedule and is given free of charge to girls born from 2000 
onwards on reaching their 12th birthday.9 Previously girls 
were vaccinated with Cervarix but in recent months Gardasil 
9 started being administered. The earl ier the vaccination, 
the betterthe response, since increasing age is linked to 
more persistent infection. Previous HPV infection does not 
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provide immunity to future infection and it is not yet known 
whether the vaccine offers lifelong protection. Males have 
the potential to be HPV carriers, therefore it may be advisable 
to offer them the HPV vaccine as well. In keeping with this, 
since September 2019 the UK has extended its vaccination 
programme to include twelve-year-old boys.6 This is a key 
factor in stopping spread of vaccine-preventable dis.eases 
and hopefully Malta will take on board free male HPV 
vaccination through the National Immunisation Schedule 
sooner rather than later. 
MALTA'S SCREENING PROGRAMME 
Women aged twenty-five to forty-nine years are offered 
screening every three years and those aged fifty to sixty-
four years are offered screening every five years.10 The 
national screening programme has been in place since 
2016 but many females were aware of the importance 
of cervical screening long before that. Unfortunately, the 
national screening programme is very poorly attended with 
less than 30% attendance rate. It is important to note that 
this is not representative of the females who are actually 
getting screened since several opt to get screened privately. 
Ideally the data from the screening programme and private 
gynaecologists is merged to get a clear idea of how many 
people are aware of cervical cancer and the need for 
screening. Until then, medical professionals are encouraged 
to promote screening to help combat cervical cancer as it is a 
preventable disease. 
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